Abbott Laboratories (NYSE:ABT) insider Daniel Gesua Sive Salvadori sold 28,319 shares of Abbott Laboratories stock in a transaction on Thursday, December 14th. The shares were sold at an average price of $54.92, for a total value of $1,555,279.48. Following the sale, the insider now directly owns 102,117 shares in the company, valued at approximately $5,608,265.64. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Daniel Gesua Sive Salvadori also recently made the following trade(s):

  • On Tuesday, November 14th, Daniel Gesua Sive Salvadori sold 71,157 shares of Abbott Laboratories stock. The shares were sold at an average price of $55.00, for a total value of $3,913,635.00.
  • On Monday, October 23rd, Daniel Gesua Sive Salvadori sold 96,603 shares of Abbott Laboratories stock. The shares were sold at an average price of $56.21, for a total value of $5,430,054.63.
  • On Tuesday, September 26th, Daniel Gesua Sive Salvadori sold 62,460 shares of Abbott Laboratories stock. The shares were sold at an average price of $52.95, for a total value of $3,307,257.00.

Shares of Abbott Laboratories (NYSE ABT) traded down $0.33 during midday trading on Thursday, hitting $54.73. The company had a trading volume of 5,935,190 shares, compared to its average volume of 5,540,000. The company has a quick ratio of 2.26, a current ratio of 2.69 and a debt-to-equity ratio of 0.72. The firm has a market cap of $95,260.00, a PE ratio of 23.11, a price-to-earnings-growth ratio of 2.09 and a beta of 1.55. Abbott Laboratories has a twelve month low of $37.90 and a twelve month high of $56.69.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Wednesday, October 18th. The healthcare product maker reported $0.66 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.01. The business had revenue of $6.83 billion for the quarter, compared to analysts’ expectations of $6.72 billion. Abbott Laboratories had a return on equity of 13.98% and a net margin of 8.37%. The company’s quarterly revenue was up 28.8% on a year-over-year basis. During the same period in the previous year, the firm posted $0.59 EPS. sell-side analysts expect that Abbott Laboratories will post 2.49 EPS for the current year.

The business also recently announced a quarterly dividend, which was paid on Wednesday, November 15th. Investors of record on Friday, October 13th were issued a $0.265 dividend. This represents a $1.06 dividend on an annualized basis and a dividend yield of 1.94%. The ex-dividend date of this dividend was Thursday, October 12th. Abbott Laboratories’s payout ratio is 87.60%.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. grew its holdings in shares of Abbott Laboratories by 2.6% during the second quarter. Vanguard Group Inc. now owns 129,786,955 shares of the healthcare product maker’s stock valued at $6,308,944,000 after buying an additional 3,241,063 shares in the last quarter. State Street Corp grew its holdings in shares of Abbott Laboratories by 18.9% during the first quarter. State Street Corp now owns 80,499,469 shares of the healthcare product maker’s stock valued at $3,574,987,000 after buying an additional 12,806,535 shares in the last quarter. Capital Research Global Investors grew its holdings in shares of Abbott Laboratories by 45.7% during the second quarter. Capital Research Global Investors now owns 47,589,663 shares of the healthcare product maker’s stock valued at $2,313,334,000 after buying an additional 14,918,038 shares in the last quarter. Northern Trust Corp grew its holdings in shares of Abbott Laboratories by 3.1% during the second quarter. Northern Trust Corp now owns 26,865,706 shares of the healthcare product maker’s stock valued at $1,305,942,000 after buying an additional 809,732 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in shares of Abbott Laboratories by 28.6% during the second quarter. Dimensional Fund Advisors LP now owns 11,722,088 shares of the healthcare product maker’s stock valued at $569,830,000 after buying an additional 2,606,404 shares in the last quarter. Institutional investors and hedge funds own 71.32% of the company’s stock.

A number of research firms have recently commented on ABT. BMO Capital Markets raised Abbott Laboratories from a “market perform” rating to an “outperform” rating and boosted their price objective for the stock from $58.00 to $65.00 in a research note on Tuesday. Barclays boosted their price objective on Abbott Laboratories from $57.00 to $60.00 and gave the stock an “overweight” rating in a research note on Thursday, September 28th. Zacks Investment Research downgraded Abbott Laboratories from a “buy” rating to a “hold” rating in a research note on Tuesday, September 26th. Stifel Nicolaus boosted their price objective on Abbott Laboratories from $58.00 to $63.00 and gave the stock a “buy” rating in a research note on Thursday, October 19th. Finally, Cowen reissued a “buy” rating on shares of Abbott Laboratories in a research note on Sunday, September 24th. Seven analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. Abbott Laboratories has a consensus rating of “Buy” and a consensus target price of $57.56.

TRADEMARK VIOLATION WARNING: This piece was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of US & international trademark and copyright law. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/12/14/abbott-laboratories-abt-insider-sells-1555279-48-in-stock.html.

About Abbott Laboratories

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Insider Buying and Selling by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.